NCT06882122View on ClinicalTrials.gov

Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions
Migraine DisorderEpisodic Migraine
Interventions
DRUG

Atogepant 60 mg

Atogepant 60 mg daily for 3 months

Trial Locations (1)

27100

RECRUITING

Headache Science & Neurorehabilitation Center, Pavia

All Listed Sponsors
lead

"IRCCS National Neurological Institute C. Mondino Foundation"

OTHER